LYCA insider filings
Lycia Therapeutics, Inc. — 24 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-04. Screen LYCA transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 24 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 12 legs across 3 filings by 9 insiders — 2,078,749 shares, $38,522,394 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
- Largest priced transaction: purchase of 1,944,444 shares @ $18.00 ($34,999,992) by Venrock Healthcare Capital Partners III, L.P., filed 2026-10-27.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
+2 more insiders in the window, not shown — every filing appears in the table below.
Recent insider filings — Lycia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management III, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners XP, L.P. — 10% owner VHCP Management XP, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Purchase (P): 8,305 @ $26.95 | EDGAR |
| 2026-10-30 | 4 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management III, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners XP, L.P. — 10% owner VHCP Management XP, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Purchase (P): 10,570 @ $25.23 · Purchase (P): 4,430 @ $25.97 · Purchase (P): 1,000 @ $26.33 · Purchase (P): 8,804 @ $26.27 · Purchase (P): 200 @ $26.86 | EDGAR |
| 2026-10-28 | 4 | Versant Ventures VII GP, L.P. — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner | Conversion (C): 5,631,425 · Conversion (C): 1,393,882 · Conversion (C): 25,390,410 (derivative) · Conversion (C): 6,284,597 (derivative) | EDGAR |
| 2026-10-27 | 4 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management III, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners XP, L.P. — 10% owner VHCP Management XP, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Purchase (P): 24,560 @ $25.68 · Purchase (P): 28,379 @ $26.11 · Conversion (C): 4,779,793 · Purchase (P): 1,944,444 @ $18 · Purchase (P): 8,261 @ $26.97 · Purchase (P): 8,729 @ $25.84 · +3 more | EDGAR |
| 2026-10-26 | 4 | Fischer Laurent — Director | Grant/award (A): 13,307 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Henderson Jane — Director | Grant/award (A): 57,666 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | RIEFLIN WILLIAM JL — Director | Grant/award (A): 24,840 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Touami Sofia — Chief Business Officer | Grant/award (A): 68,755 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Lee Chin Hyok — Chief Medical Officer, 10% owner | Grant/award (A): 73,191 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Staben Steven — Chief Scientific Officer, 10% owner | Grant/award (A): 110,896 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Bachrodt Amy — Chief Financial Officer, 10% owner | Grant/award (A): 399,746 (derivative) @ $0 | EDGAR |
| 2026-10-26 | 4 | Trombley Aetna Wun — President and CEO, Director, 10% owner | Grant/award (A): 443,586 (derivative) @ $0 | EDGAR |
| 2026-10-22 | 3 | ELI LILLY & Co — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Venrock Healthcare Capital Partners III, L.P. — 10% owner VHCP Co-Investment Holdings III, LLC — 10% owner VHCP Management III, LLC — 10% owner Venrock Healthcare Capital Partners EG, L.P. — 10% owner VHCP Management EG, LLC — 10% owner Venrock Healthcare Capital Partners XP, L.P. — 10% owner VHCP Management XP, LLC — 10% owner Koh Bong Y — 10% owner Shah Nimish P — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Bertozzi Carolyn R — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Versant Ventures VII GP, L.P. — 10% owner Versant Venture Capital VII, L.P. — 10% owner Versant Ventures VII GP-GP, LLC — 10% owner Versant Vantage II, L.P. — 10% owner Versant Vantage II GP, L.P. — 10% owner Versant Vantage II GP-GP, LLC — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Henderson Jane — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Fischer Laurent — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Touami Sofia — Chief Business Officer | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | RIEFLIN WILLIAM JL — Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Staben Steven — Chief Scientific Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Lee Chin Hyok — Chief Medical Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Bachrodt Amy — Chief Financial Officer, 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-10-22 | 3 | Trombley Aetna Wun — President and CEO, Director, 10% owner | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — Lycia Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-26 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Lycia Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299300 (S-1) — latest: Final prospectus (424B4), filed 2026-10-23
GET https://api.filingpulse.io/v1/insider-trades?ticker=LYCA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs